Lenvatinib , an oral inhibitor of vascular endothelial growth factor receptors @ , @ , and @ , fibroblast growth factor receptors @ through @ , platelet-derived growth factor receptor , RET , and KIT , showed clinical activity in a phase @ study involving patients with differentiated thyroid cancer that was refractory to radioiodine ( iodine-@ ) .